Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07419334 · ClinicalTrials.gov registry record · Phase 3
Study of ALK-001 on the Progression of Stargardt Disease
A Phase 3 study, sponsored by Alkeus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT07419334: Recruiting Phase 3 study, sponsored by Alkeus Pharmaceuticals.
NCT07419334 is a Phase 3 study that is actively recruiting participants, run by Alkeus Pharmaceuticals. The registered enrollment target is 230 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07419334, a Phase 3 study, is actively recruiting participants, sponsored by Alkeus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
Primary Outcome
Annualized growth rate of retinal atrophic lesions measured by Fundus Autofluorescence
Interventions
- DRUG Placebo
- DRUG ALK-001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2026-06 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
What NCT07419334 shows while recruiting
NCT07419334 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07419334 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07419334 about?
NCT07419334 is a clinical study titled "Study of ALK-001 on the Progression of Stargardt Disease". This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
What is the current status of trial NCT07419334?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2026-06. Estimated completion is 2030-12.
What interventions are being tested in trial NCT07419334?
The interventions under investigation include: Placebo (DRUG), ALK-001 (DRUG).
Who is sponsoring clinical trial NCT07419334?
This trial is sponsored by Alkeus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07419334's enrollment target sits among peer trials
230 1304th of 2000 higher than 692 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia